Neurogene (NASDAQ:NGNE) Now Covered by BMO Capital Markets

BMO Capital Markets assumed coverage on shares of Neurogene (NASDAQ:NGNE) in a report published on Thursday, Marketbeat.com reports. The firm issued an outperform rating and a $65.00 price target on the stock.

Other equities research analysts also recently issued reports about the company. SVB Leerink initiated coverage on Neurogene in a report on Monday, April 29th. They issued an outperform rating and a $46.00 target price on the stock. Robert W. Baird initiated coverage on Neurogene in a research note on Tuesday, June 11th. They issued an outperform rating and a $54.00 price target for the company. William Blair initiated coverage on Neurogene in a research note on Thursday, March 21st. They issued an outperform rating and a $61.00 price target for the company. Leerink Partnrs restated an outperform rating on shares of Neurogene in a research note on Monday, April 29th. Finally, Baird R W upgraded Neurogene to a strong-buy rating in a research note on Tuesday, June 11th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of Buy and a consensus price target of $51.33.

Neurogene Stock Performance

Neurogene stock opened at $36.39 on Thursday. The business has a fifty day moving average of $33.95. Neurogene has a 12 month low of $12.20 and a 12 month high of $53.00.

Neurogene (NASDAQ:NGNE) last released its earnings results on Friday, May 10th. The company reported ($1.00) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.03. On average, research analysts predict that Neurogene will post -4.15 EPS for the current year.

Institutional Trading of Neurogene

Several hedge funds have recently bought and sold shares of the stock. Baker BROS. Advisors LP grew its holdings in Neurogene by 0.6% during the first quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock valued at $23,211,000 after purchasing an additional 2,499 shares during the period. Vanguard Group Inc. grew its holdings in Neurogene by 906.5% during the first quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock valued at $25,831,000 after purchasing an additional 457,062 shares during the period. SG Americas Securities LLC bought a new stake in Neurogene during the first quarter valued at about $120,000. Privium Fund Management UK Ltd bought a new stake in Neurogene during the first quarter valued at about $274,000. Finally, Great Point Partners LLC bought a new stake in Neurogene during the fourth quarter valued at about $19,268,000. Institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.